173 results about "Ovarian tissue" patented technology

This invention provides VEGF-FSH compounds having increased serum half-lives relative to either native VEGF or FSH, in which both VEGF and FSH are biologically active. This invention also provides related compositions and methods for increasing fertility, egg production and spermatogenesis in a subject, as well as methods for increasing vascularization in a tissue, particularly in ovarian tissue.

The invention discloses a natural tissue derived ovarian acellular material and a preparation method thereof. The acellular ovarian material is prepared by processing any ovarian tissues of a mammal by virtue of a physiological saline buffer solution containing a protease inhibitor, an organic solvent solution, a PBS buffer solution containing Triton X, a PBS buffer solution containing SDS and a PBS buffer solution containing DNA enzyme. According to the ovarian acellular material provided by the invention, allogeneic or xenogeneic cells, which have immunogenicity, are removed, and meanwhile, original ECM integrity can be reserved; the ovarian acellular material has excellent extracellular microenvironment, biochemical factors, biomechanical properties and the like; and complex tissue structure of a normal ovary can be simulated to the greatest extent.

The extracorporeal culture and mature method of immature oocyte from ovary tissue block includes selecting marrow mesenchyme stem cell MSC of female mouse as the feeder cell, compounding MSC culture liquid and agar and covering the culture rack, adding HCG in 3 IU / ml, and adhering the ovary tissue block on the rack to culture. In the co-culture system, estradiol, progestin and luteotopin contents are increased obviously, and after culturing, there is mature oocyte discharged. The method is significant in surviving rear endangered species of animals, breeding fine variety of animal, cell biological research of embryo stem cell, etc.

The present invention relates to newly identified nucleic acid molecules and polypeptides present in normal and neoplastic ovarian cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to antibodies to the polypeptides of the invention, as well as agonists and antagonists of the polypeptides of the invention. The invention also relates to compositions containing the nucleic acid molecules, polypeptides, antibodies, agonists and antagonists of the invention and methods for the use of these compositions. These uses include identifying, diagnosing, monitoring, staging, imaging and treating ovarian cancer and non-cancerous disease states in ovarian, identifying ovarian tissue, monitoring and identifying and / or designing agonists and antagonists of polypeptides of the invention. The uses also include gene therapy, production of transgenic animals and cells, and production of engineered ovarian tissue for treatment and research.

The invention provides a method for knocking out a CRISPR / Cas9 mediated sheep FGF5 gene and integrating an MTNR1A gene at a fixed point.The method includes the steps of transferring the CRISPR / Cas9 targeting vector of the specific targeting third exon of the sheep FGF5 gene and the gene homologous recombination vector into a sheep fetus fibroblast to obtain a sheep FGF5 gene knockout cell with a fixed-point integration of the MTNR1A gene. The donor vector and the targeting vector are co-transfected into sheep fetus fibroblasts in a nuclear transfer mode, and specific expression of MTNR1A in sheep ovary tissue can be achieved through a CYP17 promoter in the unmarked donor vector constructed through a Gibson Assembly method. The separated and identified positive monoclonal cell strain can beused as a nuclear donor for nuclear transplantation of somatic cells to obtain cloned embryos, so that a solid foundation is laid for culturing transgenic clone sheep which locally strengthens melatonin signals and produces more hairs in a reproductive system.

The invention aims at providing an establishment method of an ovary cell line of cynoglossus semilaevis, which comprises the following steps: 1) removing the outermost membrane of the ovary tissue of cynoglossus semilaevis under a sterile condition, cutting the tissue into small blocks in a culture solution, flushing the tissue blocks with a PBS solution and digesting with a trypsin solution, wherein the solution after trypsin digestion contains cells, cell clusters and tissue blocks not completely digested; and 2) centrifuging the solution to remove the supernatant trypsin, and suspending the cells, cell clusters and small tissue block precipitates with a culture solution; after a suspension is obtained, inoculating into a culture plate treated by the type-I collagen; adding a culture solution, and culturing in a biochemical incubator at 24 DEG C; and performing subculture to finish establishment of the ovary cell line. In the establishment method provided by the invention, an ovary cell line of cynoglossus semilaevis is successfully established by use of the ovary tissue of cynoglossus semilaevis, the established cell line can be continuously passed, the passage cells obtained by the method can be passed for over 60 generations, and a great quantity of ovary cells can be provided.

The invention discloses a method for quickly and effectively transfecting mosquito by using wolbachia. According to the method, an insects ovarian tissue (abundant sources and easiness for obtaining) containing the wolbachia is directly acquired by adopting a vivisection method and is homogenated; and the ovarian tissue is separated from the wolbachia by using a centrifugation method so as to obtain a purified usable wolbachia transfected by embryonic injection. The embryo of the mosquito is injected and transfected by the purified wolbachia through a conventional method; a primary female adult insect (G0) is obtained by egg culture; the obtained primary female adult insect is mated with a wild type male mosquito to generate first generation (G1) mosquito strains; and positive mosquito strains containing the wolbachia are screened from the first generation mosquito strains and become really and successfully-transfected mosquito strains. Therefore, the method for transfecting the mosquito by using the wolbachia is a quick and effective method. The realization of the invention is beneficial to quickly establishing the mosquito strains transfected with the wolbachia and further beneficial to large-scale application of the mosquito strains.

The present invention relates to a tumor marker for diagnosis of ovarian cancer, which is selected from the group consisting of galectin-1, cathepsin B, MHC class I antigen, heat shock protein (HSP) 27, ubiquitin carboxy-termal esterase L1, plasma retinol-binding protein (PRBP), transthyretin, SH3 binding glutamate-rich protein, tubulin-specific chaperone A, RNA binding protein regulatory subunit, γ-actin, tropomyosin and calcium / calmodulin-stimulated cyclic nucleotide phosphatase. The ovarian cancer is diagnosed effectively and efficiently based on detecting the expression levels of the tumor markers in the invention from the ovarian tissue sample of an individual to be diagnosed.

A method and device for freeze-drying a biological sample of mammalian cells or tissue are disclosed. The method includes placing a biological sample on or in a structure to increase a temperature ofthe biological sample and with the biological sample in a closed chamber applying a vacuum to the chamber to lower a pressure within the chamber, cooling the chamber to lower a temperature within thechamber and applying heat to the biological sample within the chamber. The biological sample can include one or more of stem cells, hematopoietic stem cells, mesenchymal stem cells, embryonic stem cells, induced pluripotent stem cells, sperm, oocytes, embryos, ovarian tissue, uterine tissue or testicular tissue. A method for rehydration of a sample is further disclosed.

The invention relates to therapeutic and prophylactic treatment of ovarian cancer and metastases thereof. More specifically, the invention relates to immunogenic polypeptides comprising at least a portion of an ovarian tissue cell-associated protein or immunologically active variants thereof and to nucleic acids encoding such polypeptides and to the use thereof in immunotherapeutic methods of treatment. Said immunogenic polypeptides are provided by the zona pellucida (ZP) glycoproteins. ZP glycoproteins and fragments thereof that can induce a CD8+ and / or CD4+ T cell response as well as nucleic acid sequences encoding them can suitably be used in the present immunotherapeutic strategies.

The invention discloses a culture medium for 3D culture of ovarian cancer tissue, the tissue is prepared from cytokine B27, N-acetylcysteine, R-spondin 1, A83-01, epidermal growth factors, glutamine,N2Supplement, estrogen, progesterone and vitamin E. The culture medium includes various cytokines and signal pathway regulatory factors which are needed by ovarian cancer tissue cell culture, mutually, directly and closely affect each other and coordinate with each other, so that the ovarian cancer tissue cells can better display the inherent active characteristics in the process of culture, and the overall characteristic highly similar to the living ovarian cancer tissue is achieved, and ovarian tumor cells subjected to 3D culture with the culture medium are clustered and are hypoxic in the middle and similar to the ovarian tumor tissue.

The invention discloses a method for screening a miR-181b target gene. The method comprises the following steps: taking a goat ovarian tissue cDNA (complementary Deoxyribonucleic Acid) as a template and carrying out amplification in the presence of Taq DNA polymerase, a buffering environment, Mg<2+> and dNTPs by utilizing a primer RUNX1 under the condition of PCR (Polymerase Chain Reaction), so asto obtain a determined PCR product which is a sequence of a 3' UTR region of an RUNX1 gene; then constructing a dual-luciferase reporting system and detecting the activity of luciferase; primarily identifying the miR-181b target gene; detecting the influences, caused by the fact that miR-181b is detected by adopting an RT-qPCR method, on the level of an RUNX1 gene on mRNA (massager Ribonucleic Acid); detecting the influences, caused by the fact that the miR-181b is detected by adopting a Western blot method, on a protein level of the RUNX1 gene. A combination site with the miR-181b exists inthe RUNX1 3' UTR region; a modern molecular biotechnology is used for verifying a targeting regulation relation of the miR-181b and the target gene RUNX1 and the miR-181b can be used for inhibiting the expression of the RUNX1 gene in the mRNA and protein levels; furthermore, the method confirms that the RUNX1 is a target gent of the miR-181b. The method lays a foundation for further researching influences, caused by the miR-181b, on ovarian development and lambing performance of dairy goats.

The invention discloses an application of a cryoprotectant in organ and tissue cryopreservation. The cryoprotectant contains PVA, ethylene glycol and sucrose. PVA is taken as a main cryoprotectant component of the cryoprotectant, the DMSO content and toxicity are low, and the cryoprotectant has high preservation efficiency when being applied to ovarian tissues or organs. The cryoprotectant is simple in composition and can be widely applied to cryopreservation of various cells, tissues and organs; the raw materials are easily available, and the cost is low.